Is there any benefit to splitting the daily dose of quetiapine (Seroquel) between immediate‑release quetiapine fumarate and extended‑release quetiapine?

Splitting Quetiapine Dosing Between Immediate-Release and Extended-Release Formulations

Direct Answer

There is no clinical benefit to splitting the daily dose of quetiapine between immediate-release (IR) and extended-release (XR) formulations, and this practice should be avoided. The two formulations are bioequivalent when given at the same total daily dose, and combining them creates unnecessary complexity without improving efficacy, tolerability, or adherence.

---

Pharmacokinetic Evidence Against Split Dosing

Bioequivalence of formulations:

• Quetiapine XR 300 mg once daily produces an area under the curve (AUC) that is equivalent to quetiapine IR 150 mg twice daily, with a ratio of 1.04 (90% CI: 0.92–1.19), falling within the predefined equivalence range of 0.80–1.25. 1
• The XR formulation achieves a similar minimum plasma concentration (Cmin) of 95.3 ng/mL compared to 96.5 ng/mL for IR, indicating comparable trough levels throughout the 24-hour dosing interval. 1
• The only difference is that XR produces a 13% lower maximum plasma concentration (Cmax of 495.3 ng/mL versus 568.1 ng/mL for IR) and a delayed time to peak (5 hours versus 2 hours). 1, 2

Receptor occupancy profiles:

• Positron emission tomography studies demonstrate that once-daily quetiapine XR provides peak and trough dopamine D2 receptor occupancy levels comparable to twice-daily IR dosing at equivalent total daily doses (300,600, and 800 mg/day). 3
• The XR formulation exhibits a less pronounced D2 receptor occupancy peak but maintains higher receptor occupancy for a longer duration compared to IR. 2

---

Clinical Implications of the Evidence

Why split dosing offers no advantage:

• Since XR and IR formulations produce equivalent total drug exposure (AUC) and similar trough levels when dosed appropriately, splitting between formulations does not increase efficacy. 1
• The XR formulation was specifically designed to eliminate the need for twice-daily dosing by providing sustained plasma levels throughout 24 hours. 4, 5
• Combining formulations negates the primary benefit of XR—simplified once-daily administration that improves adherence in patients with schizophrenia and bipolar disorder. 4, 5

Tolerability considerations:

• The intensity of sedation in the first hours after administration is significantly lower (p < 0.01) with quetiapine XR compared to IR, which is an advantage of the XR formulation. 2
• Mixing formulations would reintroduce the rapid peak plasma levels associated with IR, potentially increasing acute sedation and dizziness. 5, 2
• The most common adverse events with both formulations—dry mouth, somnolence, dizziness, and headache—occur at similar rates and are not mitigated by split dosing. 4, 5

---

Practical Prescribing Algorithm

If a patient is currently on quetiapine IR twice daily:

• Switch directly to the same total daily dose of quetiapine XR once daily (e.g., IR 150 mg twice daily → XR 300 mg once daily). 1
• Direct switching does not result in loss of efficacy or tolerability issues. 4
• Administer XR in the evening to minimize the impact of daytime sedation. 2

If a patient is currently on quetiapine XR once daily:

• Continue XR monotherapy at the current dose; do not add IR formulation. 4, 5
• If breakthrough symptoms occur, increase the XR dose rather than adding IR. 5

If dose adjustments are needed:

• Quetiapine XR allows simple and rapid dose escalation with once-daily dosing in the range of 400–800 mg/day for schizophrenia. 5
• Dose titration is more straightforward with XR compared to IR, which requires twice-daily adjustments. 4

---

Common Pitfalls to Avoid

Do not combine formulations to "smooth out" plasma levels:

• The XR formulation already provides sustained plasma levels with less variability (coefficient of variation 39.2%) compared to IR (51.2%). 2
• Adding IR to XR would increase peak-to-trough fluctuations rather than reduce them. 1, 2

Do not use IR for "breakthrough" symptoms when on XR:

• There is no evidence supporting the use of IR for breakthrough symptoms in patients maintained on XR. 4, 5
• If symptom control is inadequate, increase the XR dose or reassess the diagnosis and treatment plan. 5

Avoid administering XR with high-fat meals:

• A high-fat meal increases the AUC and Cmax of quetiapine XR, whereas a light meal has no significant effect. 2
• Instruct patients to take XR with a light meal or on an empty stomach to maintain predictable pharmacokinetics. 2

---

Safety and Monitoring Considerations

Extrapyramidal symptoms (EPS):

• Both formulations exhibit a generally low incidence of EPS, with the most common potentially EPS-associated events being akathisia, restlessness, and tremor. 5
• Rates of worsening on the Simpson-Angus Scale and Barnes Akathisia Rating Scale are similar among quetiapine XR, quetiapine IR, and placebo. 5

Sedation management:

• The lower intensity of sedation with XR in the first hours after administration supports evening dosing to minimize daytime impairment. 2
• Combining formulations would reintroduce the rapid sedation peak associated with IR. 2

Long-term efficacy:

• Quetiapine XR significantly prolongs time to relapse compared to placebo in maintenance treatment of schizophrenia. 5
• The once-daily dosing of XR improves adherence, which is critical for preventing relapse in chronic conditions. 4, 5